Expertise in
9
conditions

Dr. Theodore F. Logan

Hematology Oncology | Oncology
University Medical Diagnostic Associates Inc
550 N University Blvd, 
Indianapolis, IN 
Accepting New Patients
Expertise in
9
conditions
University Medical Diagnostic Associates Inc
550 N University Blvd, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Theodore Logan is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Logan is highly rated in 9 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. Dr. Logan is currently accepting new patients.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Anthem
  •  WellCare Health Plans
  •  Silverscript
  •  CareSource
  •  Humana
View 7 More Insurances +

Locations

UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
550 N University Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Drug
Study Drug: Oral NKT2152
Study Phase: Phase 1/Phase 2
Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression
Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Other
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 10 Less Clinical Trials

37 Total Publications

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.
Journal: Cancer medicine
Published: October 23, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Lawrence H. Einhorn
Hematology Oncology | Oncology
Expertise in
19
conditions
Dr. Lawrence H. Einhorn
Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (0.1 mi)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Einhorn is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Einhorn is highly rated in 19 conditions, according to our data. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Orchiectomy, and Bone Marrow Transplant. Dr. Einhorn is currently accepting new patients.

Expertise in
22
conditions
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology

University Medical Diagnostic Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (0.1 mi)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nabil Adra is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Adra is highly rated in 22 conditions, according to our data. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Adra is currently accepting new patients.

Nasser H. Hanna
Expertise in
18
conditions
Dr. Nasser H. Hanna
Oncology | Hematology Oncology | Hematology
Expertise in
18
conditions
Dr. Nasser H. Hanna
Oncology | Hematology Oncology | Hematology

University Medical Diagnostic Associates Inc

11700 N Meridian St, Clarion North Medical Cente, 
Carmel, IN 
 (12.7 mi)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nasser Hanna is an Oncologist and a Hematologist Oncology provider in Carmel, Indiana. Dr. Hanna is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Hanna is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Find Dr. Logan's expertise for a condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile